Initial results from Phase I/II Study of ARV-766 in mCRPC

ASCO® 2024 Insights: Dr. Daniel Petrylak on ARV-766Подробнее

Phase 1 Trial of ARV-110 in Patients with mCRPCПодробнее

The potential role of ARV-766, an oral PROTAC AR degrader, in mCRPCПодробнее

PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPCПодробнее

PSMA ADC in prostate cancer: Phase I resultsПодробнее

A phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive mCRPCПодробнее

Results from a phase I study of AMG 160Подробнее

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant ...Подробнее

Results of Phase I Study Reach Primary End Point for mCRPCПодробнее

AR Resistance Mechanisms Focusing on Variants and TestingПодробнее

AR-V7 in Castration Resistant Prostate CancerПодробнее

LATITUDE study: major results in metastatic prostate cancerПодробнее

Long term AEs in PSMA-TRTПодробнее

PROTACs as Treatment for PCa AND Financial Toxicity & Decisional Regret in UrologyПодробнее

PSMA-TRT, 225Ac-J591 and 177Lu-PSMA I&T in mCRPCПодробнее

Phase I trial of ARX517, an anti-PSMA ADC, in mCRPCПодробнее

Prostate Cancer ResultsПодробнее

Results of a Phase II Study of LHRH Therapy in High-Risk Prostate CancerПодробнее

VISION: safety analysis of 177Lu-PSMA-617 in mCRPCПодробнее